Each year, I teach a course on medication use and policy in our PharmD program, in addition to my courses on health technology assessment and value appraisal in our graduate programs. For each of these courses, I have a “read-up” list that I go through: what’s new and should I include it in my courses? High on that list is pricing of drugs, which in the United States translates into who is and who is not, and who perhaps should be, in…